# A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

> **NCT07441278** · PHASE2 · NOT_YET_RECRUITING · sponsor: **NS Pharma, Inc.** · enrollment: 177 (estimated)

## Conditions studied

- Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

## Interventions

- **DRUG:** NS-863 Low Dose
- **DRUG:** NS-863 High Dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07441278
- **Lead sponsor:** NS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-09-14
- **Final completion:** 2028-12-14
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441278, "A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07441278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*